Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18240274 | 0.83 | ALDH1A1 (0.55) | RPS6KB1P2RX7ALDH1A1ACHESMN1; SMN2 | |
| SCHEMBL1134093 | 0.83 | P2RX7 (0.44) | RPS6KB1P2RX7OPRL1 | |
| SCHEMBL18240213 | 0.82 | RPS6KB1 (0.50) | RPS6KB1P2RX7OPRL1ALDH1A1ACHE | |
| SCHEMBL12701011 | 0.82 | OPRL1 (0.40) | RPS6KB1P2RX7OPRL1ALDH1A1ACHE | |
| SCHEMBL15129656 | 0.80 | RPS6KB1 (0.46) | RPS6KB1P2RX7OPRL1ALDH1A1ACHE | |
| SCHEMBL16460689 | 0.78 | P2RX7 (0.39) | P2RX7OPRL1ALDH1A1 | |
| SCHEMBL12701210 | 0.77 | P2RX7 (0.57) | RPS6KB1P2RX7 | |
| SCHEMBL12701269 | 0.77 | P2RX7 (0.42) | P2RX7OPRL1ALDH1A1ACHE | |
| SCHEMBL12701377 | 0.77 | OPRL1 (0.40) | RPS6KB1OPRL1ALDH1A1ACHESMN1; SMN2 | |
| SCHEMBL12701432 | 0.76 | OPRL1 (0.39) | RPS6KB1P2RX7OPRL1ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | P2RX7, P2RX1, P2RX3 | RPS6KB1 1281/4885P2RX7 1/4885OPRL1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.